Eli Lilly

In twenty nineteen, Eli Lilly had Mounjaro. It controlled blood sugar in diabetics. Researchers noticed something unexpected. The drug worked for obesity. Patients taking Mounjaro lost weight. One drug addressed two diseases. The addressable market doubled overnight. Fifty million diabetics became one hundred million potential patients immediately. Mounjaro achieved extraordinary results. Patients lost thirty percent of body weight. Competitors had nothing comparable. Insurance covered it for diabetes. Monthly cost exceeded one thousand dollars per patient. Eli Lilly sold hundreds of millions of doses yearly. Revenue exceeded three billion dollars from this single drug class within three years of approval. By twenty twenty-four, Eli Lilly became the most valuable pharmaceutical company with market cap exceeding seven hundred billion.